Digital On AI and computational support of biochemistry, with Alan R... Dr Alan Roth, CEO of Oxford Drug Design, discusses the use of AI to accelerate discovery of new treatments.
News Chai raises $130m for AI drug discovery platform AI specialist Chai Discovery has said it is sitting on a valuation of around $1.3 billion, after raising $130 million in a Series B financing.
News Lab-in-a-loop specialist Relation attracts Novartis alliance UK-based AI and multi-omics company Relation Therapeutics will seek out targets for allergic diseases on behalf of Novartis in a $1.7bn-plus alliance.
R&D Towards a democratic era of medicine, with Simon Kohl In a new episode, Simon Kohl discusses Latent Labs’ emergence from stealth, as well as protein design and drug discovery acceleration in more detail.
News Merck partners Valo on $3bn, AI-based Parkinson's project Merck has teamed up with Valo Health on a project to apply AI to the discovery of novel drug targets and drugs for Parkinson's.
News Change at the top of Recursion as co-founder leaves CEO role After 12 years as CEO of 'techbio' player Recursion, Chris Gibson is switching to the role of chair and will be replaced by Najat Khan.
News Lilly points to long-lasting weight loss with orforglipron Lilly breaks new ground for oral GLP-1 agonists with data showing it can help patients keep weight off after treatment with injectable therapies.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
